Key takeaways
Remicade (infliximab) and Cimzia (certolizumab pegol) are both injectable medications used to treat autoimmune conditions, but they have some key differences. Remicade is given through an IV infusion by a healthcare provider, while Cimzia is injected under the skin and can be self-administered. Remicade is typically given every 6 to 8 weeks, whereas Cimzia is usually given every 2 to 4 weeks. Remicade is available only as a brand-name medication, which can be expensive, but it does have several biosimilars which may make it more affordable. Cimzia is also available as brand-name medication but offers the convenience of prefilled syringes. Both medications block a protein called tumor necrosis factor (TNF) to reduce inflammation. Remicade is approved for use in children 6 years and older for certain conditions, whereas Cimzia is not approved for use in children. Additionally, Remicade requires monitoring during and after infusions for side effects, while Cimzia users need to be trained on proper injection techniques. Both medications can increase the risk of serious infections and have similar side effects.
